Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2021
Reporting Period: Single event date (September 9, 2021)
Business Context: The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Salt Lake City, Utah. Its Class A common stock trades on the Nasdaq Global Select Market under the symbol "RXRX."
Key Financial Metrics
This filing is a current report regarding a regulatory disclosure event and does not contain audited financial statements, revenue figures, profit data, cash flow statements, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
No material changes to financial performance or operational status are reported in this document. The filing serves solely to disclose the release of an updated investor presentation.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure (Item 7.01): On September 9, 2021, the company released an updated investor presentation intended for use in meetings with investors.
- Legal Status of Information: The information furnished, including the attached investor presentation (Exhibit 99.1), is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
- Incorporation by Reference: The content is not incorporated by reference into other filings under the Securities Act or Exchange Act, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation dated September 9, 2021) for specific business updates, as the 8-K text itself contains no operational details.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm that the investor presentation is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Check subsequent filings (e.g., 10-Q or 10-K) for actual financial data, as this 8-K contains none.